FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1967808511> ?p ?o ?g. }

• W1967808511 endingPage "2497" @default.
• W1967808511 startingPage "2486" @default.
• W1967808511 abstract "Abstract Anti-CD30 diabodies were engineered with two cysteine mutations for site-specific drug conjugation in each chain of these homodimeric antibody fragments. Diabodies were conjugated with ∼4 equivalents of the anti-tubulin drugs, monomethyl auristatin E or F, via a protease-cleavable dipeptide linker, to create the conjugates, diabody-vcE4 and diabody-vcF4, respectively. Diabody conjugation had only minor (&lt;3-fold) effects on antigen binding. Diabody-vcF4 was potently cytotoxic against the antigen-positive cell lines, Karpas-299 (34 pmol/L IC50) and L540cy (22 pmol/L IC50), and was 8- and 21-fold more active than diabody-vcE4 against these cell lines, respectively. Clearance of diabody-vcF4 (99-134 mL/d/kg) was 5-fold slower than for the nonconjugated diabody in naive severe combined immunodeficient mice. Diabody-vcF4 had potent and dose-dependent antitumor activity against established Karpas-299 xenografts and gave durable complete responses at well-tolerated doses. Biodistribution experiments with diabody-[3H]-vcF4 (0.72-7.2 mg/kg) in tumor-bearing mice showed a dose-dependent increase in total auristatin accumulation in tumors (≤520 nmol/L) and decrease in relative auristatin accumulation (≤8.1 %ID/g), with peak localization at 4 to 24 h after dosing. Diabody-vcF4 had ∼4-fold lower cytotoxic activity than the corresponding IgG1-vcF4 conjugate in vitro. A similar potency difference was observed in vivo despite 25- to 34-fold faster clearance of diabody-vcF4 than IgG1-vcF4. This may reflect that dose-escalated diabody-vcF4 can surpass IgG1-vcF4 in auristatin delivery to tumors, albeit with higher auristatin exposure to some organs including kidney and liver. Diabody-drug conjugates can have potent antitumor activity at well-tolerated doses and warrant further optimization for cancer therapy. [Mol Cancer Ther 2008;7(8):2486–97]" @default.
• W1967808511 created "2016-06-24" @default.
• W1967808511 creator A5010371848 @default.
• W1967808511 creator A5011719233 @default.
• W1967808511 creator A5025418128 @default.
• W1967808511 creator A5028663348 @default.
• W1967808511 creator A5036332717 @default.
• W1967808511 creator A5036438512 @default.
• W1967808511 creator A5052067361 @default.
• W1967808511 creator A5053379518 @default.
• W1967808511 creator A5058357910 @default.
• W1967808511 creator A5063558583 @default.
• W1967808511 creator A5065128818 @default.
• W1967808511 creator A5072073795 @default.
• W1967808511 creator A5084792858 @default.
• W1967808511 creator A5084910442 @default.
• W1967808511 date "2008-08-01" @default.
• W1967808511 modified "2023-10-12" @default.
• W1967808511 title "Anti-CD30 diabody-drug conjugates with potent antitumor activity" @default.
• W1967808511 cites W1979469202 @default.
• W1967808511 cites W1982501635 @default.
• W1967808511 cites W1983483937 @default.
• W1967808511 cites W1988849896 @default.
• W1967808511 cites W1993575340 @default.
• W1967808511 cites W1996820981 @default.
• W1967808511 cites W1997422287 @default.
• W1967808511 cites W1997943615 @default.
• W1967808511 cites W2006013401 @default.
• W1967808511 cites W2010147335 @default.
• W1967808511 cites W2011581231 @default.
• W1967808511 cites W2014362060 @default.
• W1967808511 cites W2023034663 @default.
• W1967808511 cites W2042557161 @default.
• W1967808511 cites W2047980903 @default.
• W1967808511 cites W2048313558 @default.
• W1967808511 cites W2065338516 @default.
• W1967808511 cites W2079294626 @default.
• W1967808511 cites W2083670340 @default.
• W1967808511 cites W2090057677 @default.
• W1967808511 cites W2099994895 @default.
• W1967808511 cites W2108146212 @default.
• W1967808511 cites W2124532648 @default.
• W1967808511 cites W2126181165 @default.
• W1967808511 cites W2133812171 @default.
• W1967808511 cites W2136101268 @default.
• W1967808511 cites W2143467722 @default.
• W1967808511 cites W2156506990 @default.
• W1967808511 cites W2159581345 @default.
• W1967808511 cites W2162183933 @default.
• W1967808511 cites W2166777850 @default.
• W1967808511 cites W2171368669 @default.
• W1967808511 cites W2247758429 @default.
• W1967808511 cites W2553809174 @default.
• W1967808511 cites W4300919850 @default.
• W1967808511 doi "https://doi.org/10.1158/1535-7163.mct-08-0388" @default.
• W1967808511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18723494" @default.
• W1967808511 hasPublicationYear "2008" @default.
• W1967808511 type Work @default.
• W1967808511 sameAs 1967808511 @default.
• W1967808511 citedByCount "83" @default.
• W1967808511 countsByYear W19678085112012 @default.
• W1967808511 countsByYear W19678085112013 @default.
• W1967808511 countsByYear W19678085112014 @default.
• W1967808511 countsByYear W19678085112015 @default.
• W1967808511 countsByYear W19678085112016 @default.
• W1967808511 countsByYear W19678085112017 @default.
• W1967808511 countsByYear W19678085112018 @default.
• W1967808511 countsByYear W19678085112019 @default.
• W1967808511 countsByYear W19678085112020 @default.
• W1967808511 countsByYear W19678085112021 @default.
• W1967808511 countsByYear W19678085112022 @default.
• W1967808511 countsByYear W19678085112023 @default.
• W1967808511 crossrefType "journal-article" @default.
• W1967808511 hasAuthorship W1967808511A5010371848 @default.
• W1967808511 hasAuthorship W1967808511A5011719233 @default.
• W1967808511 hasAuthorship W1967808511A5025418128 @default.
• W1967808511 hasAuthorship W1967808511A5028663348 @default.
• W1967808511 hasAuthorship W1967808511A5036332717 @default.
• W1967808511 hasAuthorship W1967808511A5036438512 @default.
• W1967808511 hasAuthorship W1967808511A5052067361 @default.
• W1967808511 hasAuthorship W1967808511A5053379518 @default.
• W1967808511 hasAuthorship W1967808511A5058357910 @default.
• W1967808511 hasAuthorship W1967808511A5063558583 @default.
• W1967808511 hasAuthorship W1967808511A5065128818 @default.
• W1967808511 hasAuthorship W1967808511A5072073795 @default.
• W1967808511 hasAuthorship W1967808511A5084792858 @default.
• W1967808511 hasAuthorship W1967808511A5084910442 @default.
• W1967808511 hasBestOaLocation W19678085112 @default.
• W1967808511 hasConcept C134306372 @default.
• W1967808511 hasConcept C150903083 @default.
• W1967808511 hasConcept C153911025 @default.
• W1967808511 hasConcept C154317977 @default.
• W1967808511 hasConcept C185592680 @default.
• W1967808511 hasConcept C197336794 @default.
• W1967808511 hasConcept C202751555 @default.
• W1967808511 hasConcept C207001950 @default.
• W1967808511 hasConcept C2777752497 @default.
• W1967808511 hasConcept C2777807558 @default.

• next